Minimal Residual Disease Status in Multiple Myeloma 1 Year After Autologous Hematopoietic Cell Transplantation and Lenalidomide Maintenance Are Associated With Long-Term Overall Survival.

Marcelo C Pasquini Paul K Wallace Brent R LoganManmeet KaurJoseph D TarioAlan HowardYali ZhangClaudio BrunsteinYvonne EfeberaNancy L Geller Sergio A Giralt Parameswaran N Hari Mary M HorowitzJohn KorethAmrita Y Krishnan Heather J LandauGeorge SomloNina ShahEdward StadtmauerDan T VoglDavid H VesolePhilip L McCarthy Theresa Hahn

Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)

at Y1 after AutoHCT with lenalidomide maintenance is prognostic for improved 6-year PFS and OS. Serial MRD measurements may direct trials to test how further therapy may improve long-term PFS and OS.

Keyphrases

multiple myeloma
stem cell transplantation
newly diagnosed
bone marrow
cell therapy
chronic lymphocytic leukemia
mesenchymal stem cells
free survival
high dose